Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.55 |
| ▸ | MGAM | O43451 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maackiain SCHEMBL28064249 | 1.00 | MAOA (1.00) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| Maackiain SCHEMBL29670858 | 1.00 | MAOA (1.00) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| Demethylmedicarpin SCHEMBL29843376 | 0.88 | MAOA (0.78) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| Medicarpin SCHEMBL2812444 | 0.88 | MAOA (0.78) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| Demethylmedicarpin SCHEMBL31663447 | 0.88 | MAOA (0.78) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| SCHEMBL8223903 | 0.83 | MAOA (0.71) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| SCHEMBL12891393 | 0.83 | MAOA (0.71) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| SCHEMBL12810804 | 0.83 | MAOA (0.71) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| SCHEMBL232991 | 0.81 | CYP3A4 (0.68) | MAOAMAOBCYP3A4MAPTMAPK1 | |
| SCHEMBL19999737 | 0.81 | MAOA (0.67) | MAOAMAOBCYP3A4MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9200046-B2 | Reporter system for high throughput screening of compounds and uses thereof | CORNELL UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-9200046-B2 | Reporter system for high throughput screening of compounds and uses thereof | CORNELL UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-8633203-B2 | Use of pterocarpans as active anti-cellulite ingredients | SYMRISE AG (DE) | 2014-01-21 | — | — | US | disclosed |
| US-8633203-B2 | Use of pterocarpans as active anti-cellulite ingredients | SYMRISE AG (DE) | 2014-01-21 | — | — | US | disclosed |
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2013-01-03 | — | — | US | disclosed |
| EP-2295031-A2 | Use of pterocarpans as anti-cellulite agents | Symrise AG (DE) | 2011-03-16 | — | — | EP | disclosed |
| US-20110034486-A1 | USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS | SYMRISE GMBH & CO., KG (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034486-A1 | USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS | SYMRISE GMBH & CO., KG (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | FOLDRX PHARMACEUTICALS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20090208432-A1 | AH Receptor Antagonists | SYMRISE GMBH & CO., KG (DE) | 2009-08-20 | — | — | US | disclosed |
| US-20090208432-A1 | AH Receptor Antagonists | SYMRISE GMBH & CO., KG (DE) | 2009-08-20 | — | — | US | disclosed |
| WO-2007128725-A1 | 6H-BENZOFURO[3,2-C] [1]BENZOPYRAN AND [2] BENZOPYRANO [4,3-B] [1]BENZOPYRAN DERIVATIVES AND WOOD EXTRACTS OF THESE COMPOUNDS AS ARYL HYDROCARBON RECEPTOR (AHR) ANTAGONISTS FOR THE PREVENTION OF UV-B INDUCED SKIN DAMAGE | SYMRISE GMBH & CO. KG (DE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090208432-A1 | AH Receptor Antagonists | AHR, ARNT, HCAR1 | MAOA 464/4885MAOB 544/4885CYP3A4 337/4885 |
| US-20100305068-A1 | COMPOUNDS AND METHODS FOR MODULATING PROTEIN TRAFFICKING | GOLT1B, NPC1L1, NPC1 | MAOA 4177/4885MAOB 3928/4885CYP3A4 4800/4885 |
| US-20110034486-A1 | USE OF PTEROCARPANS AS ACTIVE ANTI-CELLULITE INGREDIENTS | FABP4, PLIN1, CPT1B | MAOA 2275/4885MAOB 1827/4885CYP3A4 1262/4885 |
| US-20130005666-A1 | REPORTER SYSTEM FOR HIGH THROUGHPUT SCREENING OF COMPOUNDS AND USES THEREOF | NFE2, NFE2L2, UBE2N | MAOA 2039/4885MAOB 2318/4885CYP3A4 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.